Genzyme’s Synvisc-ONE and Myozyme Could Both See Delays After Advisory Committees
This article was originally published in The Pink Sheet Daily
Executive Summary
A Dec. 9 advisory committee meeting for the osteoarthritis pain management candidate leaves two weeks for FDA turnaround by the product’s action date.